Pre-Market Review: Delcath Systems Inc., Astex Pharma Inc., BioMarin Pharma Inc., and Akorn Inc.

 Pre-Market Review: Delcath Systems Inc., Astex Pharma Inc., BioMarin Pharma
                             Inc., and Akorn Inc.

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, August 21, 2013

LONDON, August 21, 2013 /PRNewswire/ --

The U.S. equity market posted some gains on Tuesday, August 20, 2013. The S&P
500 ended 0.38% higher at 1,652.35, and the NASDAQ Composite closed the day
0.68% higher at 3,613.59. Shares in healthcare companies ended higher,
tracking gains in the broader market. The major movers in the sector included
Delcath Systems Inc. (NASDAQ: DCTH), Astex Pharmaceuticals (NASDAQ: ASTX),
BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN), and Akorn Inc. (NASDAQ: AKRX).
AAAResearchReports.com initiated preliminary technical research on DCTH, ASTX,
BMRN, and AKRX. These free reports are accessible by signing today at:

http://www.aaaresearchreports.com/register/ 

Shares in Delcath Systems Inc. surged on Tuesday as the broader market ended
on a higher note. The company's shares oscillated between $0.30 and $0.34
before finishing the day 8.45% higher at $0.34. A total of 1.06 million shares
were traded, which is below the daily average volume of 1.43 million. The
company's stock has lost 3.25% in the last three months, underperforming the
S&P 500 which has lost 0.54% during the same period. Given the recent gains,
Delcath Systems Inc.'s stock continues to trade below its 50-day and 200-day
moving averages. The free technical analysis on DCTH is available by signing
up at:

http://www.AAAResearchReports.com/DCTH082113.pdf

Shares in Astex Pharmaceuticals Inc. edged 0.93% higher on Tuesday, extending
their gains from previous trading sessions. The company's shares fluctuated
between $5.22 and $5.47 before closing the day at $5.43. A total of 0.69
million shares were traded, which is below the daily average volume of 1.26
million. Astex Pharmaceuticals' shares have gained 5.44% in the last three
trading sessions, outperforming the S&P 500 which has lost 0.54% during the
same period. Additionally, the stock is trading above its 50-day and 200-day
moving averages. Register now to download free research on ASTX at:

http://www.AAAResearchReports.com/ASTX082113.pdf

Shares in BioMarin Pharmaceuticals Inc. rose sharply on Tuesday, finishing the
day at $63.85, up 1.70% from its previous closing price of $62.78. The
company's shares oscillated between $62.46 and $63.99. A total of 0.91 million
shares were traded, which is below the daily average volume of 1.33 million.
The stock has gained 2.27% in the last three months, compared to a loss of
0.84% in the S&P 500 during the same period. Moreover, the BioMarin
Pharmaceutical's shares are currently trading above their50-day and 200-day
moving averages. A free report on BMRN can be accessed by registering at:

http://www.AAAResearchReports.com/BMRN082113.pdf

Akorn Inc.'s shares fluctuated between $16.08 and $16.41 before finishing the
day 1.05% higher at $16.32. A total of 0.40 million shares were traded, which
is below the daily average volume of 0.56 million. The company's shares have
gained 16.99% in the last one month and 10.05% in the last three months,
outperforming the S&P 500 which has lost 2.35% and 0.84% during the respective
periods. Furthermore, the company's shares are trading above the 50-day and
200-day moving averages. Register with AAA Research Reports and download
research on AKRX for free at:

http://www.AAAResearchReports.com/AKRX082113.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA ® charterholder. However, we are only human
    and are prone to make mistakes. If you notice any errors or omissions,
    please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AAAresearchreports.com

SOURCE AAA Research Reports

Contact: Phone #: +1-(646)-396-9126, Contact Name: Peter F. Jones, Email ID:
info@aaaresearchreports.com